Rhythm Pharmaceuticals, based in Boston, develops therapeutics for rare diseases, focusing on melanocortin-4 receptor agonists like IMCIVREE, approved for chronic weight management in specific obesity cases. The company employs 226 people and went public in October 2017.
Alastair Garfield sold 1,319 shares of RYTM on 2 July at $64.60 per share, worth a total of $85K. They now own 3,132 RYTM shares, or a 30% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
